Belgian Cancer Registry

CANCER FACT SHEET 2024
OVARIAN CANCER
ICD-10 C56

CONCEPTS AND ABBREVIATIONS

Absolute numbers (N): The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

Average Annual Percentage Change (AAPC): The average relative chance in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later (=200*1.05) and 255/100,000 over 5 years (=200*$(1.05)^5$).

Crude Rate (CR): The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

ESR2013: Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

Net survival: Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

The net survival estimation was based on the regional lifetables 2024, obtained from Statbel.

Stage: Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8th edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

95% CI: 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.

Belgian Cancer Registry

TABLE OF CONTENTS

1. CANCER INCIDENCE 5

1.1. Ovarian cancer incidence: by region 5

1.1.1. Ovarian cancer incidence by region: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024 5

1.2. Ovarian cancer incidence: by tumour stage 6

1.2.1. Ovarian cancer incidence by clinical stage (cStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 6

1.2.2. Ovarian cancer incidence by pathological stage (pStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 6

1.2.3. Ovarian cancer incidence by stage and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 7

1.2.4. Ovarian cancer incidence by tumour type and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 7

1.2.5. Ovarian cancer incidence by tumour type, stage and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 8

2. CANCER INCIDENCE TRENDS 10

2.1. Ovarian cancer incidence trends: by region 10

2.1.1. Ovarian cancer incidence trends by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 10

2.2. Ovarian cancer incidence trends: by tumour stage 11

2.2.1. Ovarian cancer incidence trends by stage: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards 11

2.3. Ovarian cancer incidence trends: by age group 12

2.3.1. Ovarian cancer incidence trends by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 12

3. CANCER PREVALENCE 13

3.1. Ovarian cancer prevalence: by region 13

3.1.1. Ovarian cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024 13

4. CANCER SURVIVAL 14

4.1. Ovarian cancer survival: by region 14

4.1.1. Ovarian cancer survival by region and age group: number at risk and net survival probabilities, 2015-2024 14

4.2. Ovarian cancer survival: by tumour type and tumour stage 16

4.2.1. Ovarian cancer survival by type and clinical stage (cStage): number at risk and net survival probabilities, 2015-2024 16

4.2.2. Ovarian cancer survival by type and pathological stage (pStage): number at risk and net survival probabilities, 2015-2024 19

4.2.3. Ovarian cancer survival by type and stage: number at risk and net survival probabilities, 2015-2024 22

5. CANCER SURVIVAL TRENDS 25

5.1. Ovarian cancer survival trends: by tumour stage 25

5.1.1. Ovarian cancer survival trends by stage: number at risk and net survival probabilities, 2004-2024 25
5.2. Ovarian cancer survival trends: by tumour type and tumour stage 27
5.2.1. Ovarian cancer survival trends by type and stage: number at risk and net survival probabilities, 2004-2024 27
6. CANCER MORTALITY 37
6.1. Ovarian cancer mortality: by region 37
6.1.1. Ovarian cancer mortality* by region: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023 37
7. CANCER MORTALITY TRENDS 38
7.1. Ovarian cancer mortality trends: by region 38
7.1.1. Ovarian cancer mortality* trends by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023 38

1.1. Ovarian cancer incidence: by region

1.1.1. Ovarian cancer incidence by region: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024

	N [CR]																				ESR2013 (95%CI)
Region	**0-**	**5-**	**10-**	**15-**	**20-**	**25-**	**30-**	**35-**	**40-**	**45-**	**50-**	**55-**	**60-**	**65-**	**70-**	**75-**	**80-**	**85-**	**90-**	**95-**	**All ages**	
Females																						
Belgium	1	0	1	5	6	11	15	9	20	31	48	49	85	108	111	110	84	50	21	4	769	12.1
	[0.3]	[0.0]	[0.3]	[1.5]	[1.8]	[3.0]	[3.8]	[2.3]	[5.2]	[8.4]	[12.5]	[12.5]	[22.0]	[31.3]	[37.2]	[43.0]	[48.3]	[36.9]	[29.2]	[18.5]	[12.9]	(11.2; 13.0)
Brussels	0	0	0	0	1	3	4	4	4	5	2	1	9	5	7	6	6	2	2	1	62	11.2
	[0.0]	[0.0]	[0.0]	[0.0]	[2.3]	[5.3]	[7.3]	[8.2]	[8.8]	[11.9]	[5.2]	[2.9]	[29.5]	[19.9]	[32.5]	[32.4]	[46.8]	[20.7]	[35.4]	[47.6]	[9.7]	(8.3; 14.0)
Flanders	1	0	0	3	1	4	10	4	9	18	30	35	50	69	78	62	57	34	14	3	482	12.6
	[0.6]	[0.0]	[0.0]	[1.6]	[0.5]	[2.0]	[4.6]	[1.9]	[4.0]	[8.5]	[13.5]	[15.0]	[21.6]	[33.4]	[44.0]	[40.1]	[52.0]	[39.2]	[30.9]	[23.3]	[14.0]	(11.5; 13.8)
Wallonia	0	0	1	2	4	4	1	1	7	8	16	13	26	34	26	42	21	14	5	0	225	11.2
	[0.0]	[0.0]	[0.9]	[1.8]	[3.6]	[3.8]	[0.8]	[0.8]	[5.9]	[6.8]	[12.8]	[10.4]	[21.0]	[30.1]	[26.0]	[50.7]	[40.8]	[35.8]	[23.7]	[0.0]	[11.9]	(9.7; 12.6)

1.2. Ovarian cancer incidence: by tumour stage

1.2.1. Ovarian cancer incidence by clinical stage (cStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

cStage	N[CR]				ESR2013 (95%CI)
	15-54	55-74	75+	All ages 0+	
I	54 [1.8]	79 [5.6]	37 [5.6]	171 [2.9]	2.8 (2.3; 3.2)
II	3 [0.1]	19 [1.3]	9 [1.4]	32 [0.5]	0.5 (0.3; 0.7)
III	45 [1.5]	120 [8.4]	95 [14.4]	260 [4.4]	4.1 (3.6; 4.6)
IV	22 [0.7]	107 [7.5]	97 [14.7]	226 [3.8]	3.5 (3.0; 3.9)
X/NA	21 [0.7]	28 [2.0]	31 [4.7]	80 [1.3]	1.2 (1.0; 1.5)

1.2.2. Ovarian cancer incidence by pathological stage (pStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

pStage	N[CR]				ESR2013 (95%CI)
	15-54	55-74	75+	All ages 0+	
I	59 [2.0]	86 [6.0]	31 [4.7]	177 [3.0]	2.9 (2.5; 3.3)
II	6 [0.2]	22 [1.5]	10 [1.5]	38 [0.6]	0.6 (0.4; 0.8)
III	42 [1.4]	131 [9.2]	61 [9.3]	234 [3.9]	3.8 (3.3; 4.3)
IV	18 [0.6]	42 [3.0]	15 [2.3]	75 [1.3]	1.2 (1.0; 1.5)
X/NA	20 [0.7]	72 [5.1]	152 [23.1]	245 [4.1]	3.6 (3.1; 4.0)

1.2.3. Ovarian cancer incidence by stage and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Stage	N[CR]				ESR2013 (95%CI)
	15-54	55-74	75+	All ages 0+	
I	62 [2.1]	84 [5.9]	36 [5.5]	183 [3.1]	3.0 (2.5; 3.4)
II	6 [0.2]	17 [1.2]	11 [1.7]	35 [0.6]	0.6 (0.4; 0.7)
III	36 [1.2]	129 [9.1]	99 [15.0]	264 [4.4]	4.2 (3.6; 4.7)
IV	33 [1.1]	113 [7.9]	99 [15.0]	245 [4.1]	3.8 (3.3; 4.3)
X/NA	8 [0.3]	10 [0.7]	24 [3.6]	42 [0.7]	0.6 (0.4; 0.8)

1.2.4. Ovarian cancer incidence by tumour type and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Type	Grade	N[CR]				ESR2013 (95%CI)
		15-54	55-74	75+	All ages 0+	
Serous carcinoma		66 [2.2]	263 [18.5]	179 [27.2]	508 [8.5]	8.0 (7.3; 8.7)
	Low-grade	17 [0.6]	23 [1.6]	10 [1.5]	50 [0.8]	0.8 (0.6; 1.0)
	High-grade	49 [1.7]	239 [16.8]	164 [24.9]	452 [7.6]	7.1 (6.4; 7.8)
	Unspecified	0 [0.0]	1 [0.1]	5 [0.8]	6 [0.1]	0.1 (0.0; 0.1)
Mucinous carcinoma		15 [0.5]	21 [1.5]	10 [1.5]	46 [0.8]	0.7 (0.5; 1.0)
Endometrioid carcinoma		14 [0.5]	13 [0.9]	8 [1.2]	35 [0.6]	0.6 (0.4; 0.8)
Clear-cell carcinoma		8 [0.3]	13 [0.9]	6 [0.9]	27 [0.5]	0.4 (0.3; 0.6)
Adenocarcinoma		4 [0.1]	10 [0.7]	17 [2.6]	31 [0.5]	0.5 (0.3; 0.6)
Other and unspecified		38 [1.3]	33 [2.3]	49 [7.4]	122 [2.0]	1.9 (1.5; 2.2)

1.2.5. Ovarian cancer incidence by tumour type, stage and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

			N[CR]				ESR2013 (95%CI)
Type	**Grade**	**Stage**	**15-54**	**55-74**	**75+**	**All ages 0+**	
Serous carcinoma		I	9 [0.3]	28 [2.0]	10 [1.5]	47 [0.8]	0.7 (0.5; 1.0)
		II	3 [0.1]	11 [0.8]	5 [0.8]	19 [0.3]	0.3 (0.2; 0.4)
		III	32 [1.1]	120 [8.4]	70 [10.6]	222 [3.7]	3.5 (3.1; 4.0)
		IV	20 [0.7]	96 [6.8]	78 [11.8]	194 [3.3]	3.0 (2.6; 3.5)
		X/NA	2 [0.1]	8 [0.6]	16 [2.4]	26 [0.4]	0.4 (0.2; 0.5)
	Low-grade	I	2 [0.1]	8 [0.6]	2 [0.3]	12 [0.2]	0.2 (0.1; 0.3)
		II	0 [0.0]	3 [0.2]	0 [0.0]	3 [0.1]	0.0 (0.0; 0.1)
		III	10 [0.3]	7 [0.5]	2 [0.3]	19 [0.3]	0.3 (0.2; 0.5)
		IV	4 [0.1]	5 [0.4]	6 [0.9]	15 [0.3]	0.2 (0.1; 0.4)
		X/NA	1 [0.0]	0 [0.0]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.1)
	High-grade	I	7 [0.2]	20 [1.4]	8 [1.2]	35 [0.6]	0.6 (0.4; 0.7)
		II	3 [0.1]	8 [0.6]	5 [0.8]	16 [0.3]	0.3 (0.1; 0.4)
		III	22 [0.7]	113 [7.9]	68 [10.3]	203 [3.4]	3.2 (2.8; 3.7)
		IV	16 [0.5]	91 [6.4]	72 [10.9]	179 [3.0]	2.8 (2.4; 3.2)
		X/NA	1 [0.0]	7 [0.5]	11 [1.7]	19 [0.3]	0.3 (0.2; 0.4)
	Unspecified	I	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
		II	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
		III	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
		IV	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
		X/NA	0 [0.0]	1 [0.1]	5 [0.8]	6 [0.1]	0.1 (0.0; 0.1)
Mucinous carcinoma		I	14 [0.5]	20 [1.4]	6 [0.9]	40 [0.7]	0.7 (0.5; 0.9)
		II	0 [0.0]	0 [0.0]	1 [0.2]	1 [0.0]	0.0 (0.0; 0.0)

Type	Grade	Stage	N[CR] 15-54	55-74	75+	All ages 0+	ESR2013 (95%CI)
		III	1 [0.0]	0 [0.0]	3 [0.5]	4 [0.1]	0.1 (0.0; 0.1)
		IV	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
		X/NA	0 [0.0]	1 [0.1]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.0)
Endometrioid carcinoma		I	10 [0.3]	11 [0.8]	4 [0.6]	25 [0.4]	0.4 (0.3; 0.6)
		II	1 [0.0]	1 [0.1]	2 [0.3]	4 [0.1]	0.1 (0.0; 0.1)
		III	2 [0.1]	0 [0.0]	2 [0.3]	4 [0.1]	0.1 (0.0; 0.1)
		IV	1 [0.0]	1 [0.1]	0 [0.0]	2 [0.0]	0.0 (0.0; 0.1)
		X/NA	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
Clear-cell carcinoma		I	5 [0.2]	9 [0.6]	4 [0.6]	18 [0.3]	0.3 (0.2; 0.4)
		II	0 [0.0]	1 [0.1]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.0)
		III	0 [0.0]	2 [0.1]	0 [0.0]	2 [0.0]	0.0 (0.0; 0.1)
		IV	3 [0.1]	1 [0.1]	0 [0.0]	4 [0.1]	0.1 (0.0; 0.1)
		X/NA	0 [0.0]	0 [0.0]	2 [0.3]	2 [0.0]	0.0 (0.0; 0.1)
Adenocarcinoma		I	3 [0.1]	2 [0.1]	1 [0.2]	6 [0.1]	0.1 (0.0; 0.2)
		II	1 [0.0]	1 [0.1]	1 [0.2]	3 [0.1]	0.0 (0.0; 0.1)
		III	0 [0.0]	1 [0.1]	5 [0.8]	6 [0.1]	0.1 (0.0; 0.2)
		IV	0 [0.0]	6 [0.4]	9 [1.4]	15 [0.3]	0.2 (0.1; 0.3)
		X/NA	0 [0.0]	0 [0.0]	1 [0.2]	1 [0.0]	0.0 (0.0; 0.0)
Other and unspecified		I	21 [0.7]	14 [1.0]	11 [1.7]	47 [0.8]	0.8 (0.5; 1.0)
		II	1 [0.0]	3 [0.2]	2 [0.3]	7 [0.1]	0.1 (0.0; 0.2)
		III	1 [0.0]	6 [0.4]	19 [2.9]	26 [0.4]	0.4 (0.2; 0.5)
		IV	9 [0.3]	9 [0.6]	12 [1.8]	30 [0.5]	0.5 (0.3; 0.6)
		X/NA	6 [0.2]	1 [0.1]	5 [0.8]	12 [0.2]	0.2 (0.1; 0.3)

2.1. Ovarian cancer incidence trends: by region

2.1.1. Ovarian cancer incidence trends by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
Belgium	**N**	910	931	921	923	876	784	860	830	801	775	837	802	736	769	737	714	812	799	749	707	769		
	CR	17.1	17.5	17.2	17.1	16.1	14.3	15.6	14.9	14.2	13.7	14.7	14.1	12.8	13.4	12.8	12.3	13.9	13.7	12.7	11.9	12.9		
	ESR2013	17.8	17.7	17.6	17.4	16.2	14.3	15.6	14.9	14.2	13.6	14.6	13.9	12.6	13.1	12.3	11.8	13.4	13.1	12.1	11.2	12.1	-2.1 (-2.5; -1.8)	2004-2024
Brussels	**N**	73	87	63	77	78	62	77	75	64	48	75	60	62	60	60	56	75	88	59	65	62		
	CR	14.1	16.6	11.9	14.4	14.4	11.2	13.7	13.0	10.9	8.1	12.6	10.0	10.2	9.8	9.8	9.1	12.1	14.2	9.5	10.3	9.7		
	ESR2013	16.2	18.7	13.9	16.0	16.2	13.8	15.9	15.0	12.6	9.5	14.8	12.7	12.1	12.2	12.0	10.9	15.1	16.9	11.8	12.8	11.2	-1.4 (-2.5; -0.3)	2004-2024
Flanders	**N**	561	557	581	544	534	476	505	506	483	473	485	492	443	475	456	440	490	469	477	415	482		
	CR	18.4	18.2	18.9	17.5	17.1	15.1	15.9	15.8	15.0	14.6	14.9	15.1	13.5	14.4	13.8	13.2	14.6	14.0	14.1	12.1	14.0		
	ESR2013	18.8	18.1	18.8	17.4	16.7	14.7	15.4	15.3	14.5	14.0	14.1	14.3	12.8	13.4	12.8	12.1	13.4	12.7	12.8	10.8	12.6	-2.3 (-2.7; -1.9)	2004-2024
																							-3.3 (-4.2; -2.4)	2004-2013
																							-1.5 (-2.2; -0.7)	2014-2024
Wallonia	**N**	276	287	277	302	264	246	278	249	254	254	277	250	231	234	221	218	247	242	213	227	225		
	CR	15.9	16.4	15.8	17.1	14.8	13.8	15.5	13.7	13.9	13.9	15.1	13.6	12.5	12.6	11.9	11.7	13.3	13.0	11.4	12.1	11.9		
	ESR2013	16.4	17.0	16.3	17.6	15.3	13.8	15.9	13.8	14.2	14.1	15.2	13.4	12.2	12.5	11.5	11.3	13.1	12.6	10.8	11.5	11.2	-2.2 (-2.6; -1.7)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.2. Ovarian cancer incidence trends: by tumour stage

2.2.1. Ovarian cancer incidence trends by stage: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards

Stage		2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
I	N	159	185	171	183	183		
	CR	2.7	3.2	2.9	3.1	3.1		
	ESR2013	2.7	3.1	2.9	3.0	3.0	0.6 (-0.3; 1.5)	2004-2024
II	N	49	50	42	30	35		
	CR	0.8	0.9	0.7	0.5	0.6		
	ESR2013	0.8	0.8	0.7	0.5	0.6	-2.0 (-3.5; -0.5)	2004-2024
III	N	247	249	266	226	264		
	CR	4.2	4.3	4.5	3.8	4.4		
	ESR2013	4.1	4.1	4.3	3.6	4.2	-0.2 (-0.8; 0.4)	2004-2024
							1.4 (-0.1; 3.0)	2004-2013
							-1.5 (-2.7; -0.3)	2014-2024
IV	N	265	275	239	234	245		
	CR	4.5	4.7	4.1	3.9	4.1		
	ESR2013	4.4	4.5	3.8	3.6	3.8	2.3 (1.4; 3.2)	2004-2024
X/NA	N	92	40	31	34	42		
	CR	1.6	0.7	0.5	0.6	0.7		
	ESR2013	1.4	0.6	0.5	0.5	0.6	-13.3 (-14.8; -11.7)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3. Ovarian cancer incidence trends: by age group

2.3.1. Ovarian cancer incidence trends by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, %	(95%CI)	Period
15-54	**N**	209	228	201	219	185	162	175	157	189	160	156	154	157	145	150	142	131	153	127	107	145			
	CR	7.4	8.1	7.1	7.7	6.5	5.6	6.1	5.4	6.5	5.5	5.4	5.3	5.4	5.0	5.2	4.9	4.5	5.3	4.4	3.6	4.9			
	ESR2013	7.7	8.2	7.2	7.8	6.5	5.7	6.1	5.4	6.5	5.5	5.3	5.3	5.4	5.0	5.2	4.9	4.6	5.4	4.5	3.7	5.0	-2.8	(-3.5; -2.1)	2004-2024
55-74	**N**	458	419	459	446	424	376	422	382	371	369	394	385	341	385	334	332	387	377	371	327	353			
	CR	41.8	38.0	41.4	39.9	37.6	33.0	36.5	32.5	31.1	30.4	32.0	30.8	26.8	29.5	25.1	24.5	28.1	27.0	26.4	23.1	24.8			
	ESR2013	41.9	37.6	41.4	40.1	37.7	33.2	36.7	32.9	31.5	30.8	32.6	31.6	27.3	30.1	25.3	24.7	28.3	27.2	26.6	23.2	24.8	-2.7	(-3.2; -2.3)	2004-2024
75+	**N**	242	281	261	252	266	241	263	282	239	244	285	261	235	238	249	237	292	265	250	268	269			
	CR	46.6	52.9	47.9	45.2	46.7	41.7	44.8	47.5	39.8	40.4	46.7	42.3	38.1	38.9	40.7	38.6	47.1	42.8	39.4	41.5	40.8			
	ESR2013	46.0	52.8	47.5	44.6	46.0	40.7	44.4	47.9	40.0	40.5	47.1	42.7	38.6	39.3	41.2	38.5	49.6	44.2	40.3	42.7	41.7	-0.6	(-1.2; -0.1)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

3.1. Ovarian cancer prevalence: by region

3.1.1. Ovarian cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024

Region		Females				
		1-year	5-year	10-year	15-year	20-year
Belgium	**N**	652	2,351	3,652	4,600	5,498
	CR	10.9	39.2	60.9	77	92
	ESR2013	10.3	37.2	57.7	72.4	86.1
Brussels	**N**	55	222	330	407	476
	CR	8.6	34.7	51.5	63.5	74.3
	ESR2013	9.9	41.6	62.3	76.9	90.1
Flanders	**N**	408	1,426	2,230	2,825	3,403
	CR	11.8	41.2	64.4	81.5	98.2
	ESR2013	10.8	37.6	58.7	74.1	88.8
Wallonia	**N**	189	703	1,092	1,368	1,619
	CR	10.0	37.2	57.8	72.4	85.7
	ESR2013	9.3	35.0	54.3	67.9	80.0

4.1. Ovarian cancer survival: by region

4.1.1. Ovarian cancer survival by region and age group: number at risk and net survival probabilities, 2015-2024

			Net Survival Probability, 2015-2024			
Region	**Age**	**N at risk**	**1-y (95%CI)**	**3-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Females						
Belgium	**All ages 15+**	7,540	78.8% (77.8%; 79.8%)	58.7% (57.4%; 59.9%)	46.8% (45.4%; 48.2%)	37.5% (35.2%; 39.9%)
	15-54	1,285	93.5% (92.1%; 94.9%)	82.0% (79.8%; 84.2%)	72.0% (69.3%; 74.8%)	60.3% (56.8%; 64.0%)
	55-74	3,581	86.7% (85.6%; 87.9%)	65.1% (63.5%; 66.8%)	50.4% (48.5%; 52.4%)	39.1% (36.6%; 41.6%)
	75+	2,555	59.8% (57.8%; 61.9%)	37.3% (35.1%; 39.6%)	28.1% (25.7%; 30.7%)	22.9% (18.2%; 28.9%)
Brussels	**All ages 15+**	637	82.8% (79.8%; 86.0%)	66.1% (62.0%; 70.4%)	52.5% (47.8%; 57.6%)	41.5% (32.2%; 53.6%)
	15-54	170	94.7% (91.3%; 98.2%)	84.8% (79.2%; 90.8%)	74.0% (66.8%; 82.0%)	68.2% (59.8%; 77.8%)
	55-74	282	84.2% (79.9%; 88.7%)	67.8% (62.1%; 73.9%)	51.1% (44.6%; 58.5%)	40.6% (32.2%; 51.2%)
	75+	175	68.8% (61.7%; 76.8%)	46.1% (37.8%; 56.1%)	34.5% (25.8%; 46.3%)	22.2% (9.2%; 53.6%)
Flanders	**All ages 15+**	4,608	78.2% (76.9%; 79.4%)	58.6% (57.0%; 60.2%)	46.8% (45.1%; 48.6%)	38.3% (35.5%; 41.4%)
	15-54	685	93.5% (91.7%; 95.4%)	81.3% (78.3%; 84.4%)	71.7% (68.1%; 75.5%)	58.9% (54.0%; 64.1%)
	55-74	2,193	87.3% (85.9%; 88.8%)	66.3% (64.2%; 68.4%)	52.1% (49.7%; 54.6%)	39.5% (36.5%; 42.9%)
	75+	1,649	59.1% (56.6%; 61.7%)	38.4% (35.7%; 41.3%)	28.4% (25.5%; 31.6%)	26.5% (20.8%; 33.8%)
Wallonia	**All ages 15+**	2,295	78.9% (77.2%; 80.7%)	56.8% (54.6%; 59.1%)	45.3% (42.8%; 47.8%)	34.6% (30.9%; 38.7%)
	15-54	430	92.9% (90.5%; 95.4%)	81.9% (78.1%; 85.8%)	71.6% (67.0%; 76.5%)	59.8% (53.9%; 66.3%)

Net Survival Probability, 2015-2024						
Region	**Age**	**N at risk**	**1-y (95%CI)**	**3-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
	55-74	1,106	86.2% (84.1%; 88.3%)	62.2% (59.2%; 65.4%)	46.9% (43.5%; 50.5%)	37.6% (33.6%; 42.1%)
	75+	731	59.3% (55.6%; 63.3%)	32.8% (29.0%; 37.2%)	25.4% (21.4%; 30.2%)	12.6% (6.4%; 24.5%)

4.2. Ovarian cancer survival: by tumour type and tumour stage

4.2.1. Ovarian cancer survival by type and clinical stage (cStage): number at risk and net survival probabilities, 2015-2024

			Net Survival Probability, 2015-2024						
Type	**Grade**	**cStage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Ovary		All	7,540	78.8% (77.8%; 79.8%)	68.0% (66.8%; 69.1%)	58.7% (57.4%; 59.9%)	51.9% (50.6%; 53.2%)	46.8% (45.4%; 48.2%)	37.5% (35.2%; 39.9%)
		I	1,124	96.4% (95.0%; 97.7%)	94.5% (92.7%; 96.3%)	92.1% (89.9%; 94.4%)	89.7% (86.9%; 92.5%)	88.9% (85.8%; 92.1%)	91.1% (85.3%; 97.3%)
		II	251	86.3% (81.7%; 91.1%)	79.5% (74.0%; 85.3%)	77.3% (71.3%; 83.8%)	74.7% (68.0%; 82.0%)	69.1% (61.5%; 77.7%)	58.8% (44.1%; 78.4%)
		III	2,044	79.4% (77.5%; 81.2%)	66.6% (64.4%; 68.9%)	55.0% (52.6%; 57.4%)	44.3% (41.8%; 46.9%)	36.9% (34.4%; 39.7%)	28.4% (24.3%; 33.2%)
		IV	2,083	66.1% (64.0%; 68.3%)	48.7% (46.5%; 51.1%)	34.1% (31.9%; 36.4%)	25.8% (23.7%; 28.0%)	18.8% (16.9%; 21.0%)	10.2% (7.8%; 13.2%)
		X/NA	2,042	80.5% (78.7%; 82.4%)	72.9% (70.9%; 75.1%)	66.6% (64.4%; 68.9%)	62.1% (59.8%; 64.5%)	58.7% (56.2%; 61.3%)	47.0% (43.0%; 51.3%)
Serous carcinoma		All	4,807	81.6% (80.5%; 82.8%)	68.1% (66.7%; 69.6%)	56.0% (54.5%; 57.6%)	46.2% (44.6%; 47.9%)	39.5% (37.9%; 41.3%)	24.6% (22.3%; 27.2%)
		I	332	96.8% (94.5%; 99.3%)	93.9% (90.5%; 97.4%)	89.7% (85.3%; 94.2%)	84.4% (78.9%; 90.4%)	82.6% (76.4%; 89.4%)	80.2% (67.9%; 94.8%)
		II	152	93.6% (89.3%; 98.2%)	83.0% (76.5%; 90.0%)	79.4% (72.3%; 87.3%)	74.4% (66.2%; 83.7%)	67.3% (58.2%; 77.8%)	47.0% (30.7%; 71.9%)
		III	1,641	85.3% (83.4%; 87.1%)	72.0% (69.6%; 74.4%)	59.5% (56.8%; 62.2%)	46.9% (44.2%; 49.9%)	38.4% (35.5%; 41.5%)	20.1% (16.1%; 25.0%)
		IV	1,609	74.3% (72.1%; 76.6%)	55.8% (53.3%; 58.5%)	39.7% (37.1%; 42.4%)	29.7% (27.2%; 32.4%)	22.3% (19.9%; 25.0%)	10.9% (8.1%; 14.7%)
		X/NA	1,073	80.6% (78.1%; 83.1%)	70.6% (67.7%; 73.6%)	61.4% (58.3%; 64.7%)	53.4% (50.1%; 56.8%)	48.5% (45.2%; 52.0%)	31.9% (27.7%; 36.8%)
	Low-grade	All	541	85.4% (82.3%; 88.6%)	77.7% (74.0%; 81.6%)	71.3% (67.2%; 75.8%)	63.6% (59.0%; 68.5%)	57.1% (52.3%; 62.4%)	40.2% (33.1%; 48.9%)
		I	58	98.3% (95.0%; 101.7%)	99.2% (94.5%; 104.1%)	98.6% (92.3%; 105.2%)	96.9% (87.0%; 107.9%)	96.0% (84.8%; 108.7%)	91.4% (71.7%; 116.5%)
		II	21	N<50	N<50	N<50	N<50	N<50	N<50
		III	154	88.5% (83.2%; 94.1%)	80.5% (73.8%; 87.8%)	72.1% (64.4%; 80.7%)	62.6% (54.0%; 72.5%)	51.2% (42.1%; 62.3%)	31.4% (19.0%; 51.9%)
		IV	124	71.3% (63.6%; 80.0%)	55.2% (46.8%; 65.1%)	45.2% (36.7%; 55.6%)	33.4% (25.2%; 44.1%)	24.3% (16.8%; 35.1%)	FU<10y
		X/NA	184	86.5% (81.4%; 91.9%)	82.3% (76.4%; 88.6%)	77.2% (70.6%; 84.4%)	70.5% (63.3%; 78.5%)	67.8% (60.3%; 76.3%)	50.8% (40.6%; 63.6%)
	High-grade	All	4,199	81.6% (80.3%; 82.8%)	67.3% (65.8%; 68.8%)	54.4% (52.7%; 56.1%)	44.2% (42.5%; 46.0%)	37.4% (35.6%; 39.2%)	22.4% (19.8%; 25.2%)
		I	273	96.2% (93.5%; 99.1%)	92.7% (88.8%; 96.8%)	87.6% (82.6%; 93.0%)	81.6% (75.3%; 88.4%)	79.6% (72.6%; 87.4%)	77.4% (63.4%; 94.5%)
		II	130	93.2% (88.5%; 98.3%)	81.6% (74.4%; 89.4%)	77.3% (69.3%; 86.2%)	70.9% (61.7%; 81.4%)	65.2% (55.2%; 76.9%)	39.0% (22.4%; 67.9%)

Net Survival Probability, 2015-2024									
Type	**Grade**	**cStage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
		III	1,482	84.9% (83.0%; 86.9%)	71.1% (68.6%; 73.7%)	58.2% (55.4%; 61.2%)	45.4% (42.5%; 48.6%)	37.3% (34.3%; 40.5%)	19.0% (14.9%; 24.1%)
		IV	1,472	74.4% (72.1%; 76.8%)	55.8% (53.1%; 58.6%)	39.2% (36.5%; 42.0%)	29.4% (26.8%; 32.3%)	22.0% (19.6%; 24.8%)	11.3% (8.5%; 15.2%)
		X/NA	842	81.4% (78.7%; 84.3%)	70.2% (66.9%; 73.6%)	59.7% (56.1%; 63.4%)	51.0% (47.4%; 54.9%)	45.4% (41.7%; 49.4%)	28.4% (23.7%; 34.0%)
	Unspecified	All	67	54.1% (43.0%; 68.1%)	42.1% (31.2%; 56.7%)	35.8% (25.3%; 50.8%)	29.1% (19.3%; 43.9%)	27.8% (18.2%; 42.6%)	23.5% (13.5%; 40.8%)
		I	1	N<50	N<50	N<50	N<50	N<50	N<50
		II	1	N<50	N<50	N<50	N<50	N<50	N<50
		III	5	N<50	N<50	N<50	N<50	N<50	N<50
		IV	13	N<50	N<50	N<50	N<50	N<50	N<50
		X/NA	47	N<50	N<50	N<50	N<50	N<50	N<50
Mucinous carcinoma		All	528	85.0% (81.9%; 88.3%)	80.5% (76.8%; 84.3%)	77.7% (73.7%; 81.9%)	77.1% (72.9%; 81.6%)	75.0% (70.4%; 79.9%)	69.3% (60.5%; 79.4%)
		I	227	98.3% (96.0%; 100.7%)	96.6% (92.9%; 100.3%)	95.3% (90.9%; 99.9%)	94.9% (89.9%; 100.2%)	94.2% (88.3%; 100.5%)	108.0% (96.9%; 120.5%)
		II	14	N<50	N<50	N<50	N<50	N<50	N<50
		III	51	60.4% (48.1%; 75.8%)	51.6% (39.1%; 68.1%)	45.8% (33.2%; 63.2%)	41.9% (29.0%; 60.5%)	41.9% (29.0%; 60.5%)	43.8% (27.9%; 68.6%)
		IV	46	N<50	N<50	N<50	N<50	N<50	N<50
		X/NA	190	87.3% (82.5%; 92.4%)	84.7% (79.4%; 90.5%)	82.6% (76.7%; 88.9%)	82.8% (76.7%; 89.4%)	80.1% (73.3%; 87.5%)	66.2% (54.0%; 81.0%)
Endometrioid carcinoma		All	478	95.8% (93.6%; 98.0%)	93.3% (90.5%; 96.3%)	91.6% (88.2%; 95.1%)	89.3% (85.3%; 93.5%)	87.0% (82.4%; 92.0%)	82.4% (70.4%; 96.5%)
		I	186	100.3% (98.8%; 101.8%)	99.8% (96.8%; 102.9%)	99.7% (95.6%; 103.9%)	99.7% (94.1%; 105.6%)	99.9% (93.4%; 106.8%)	106.7% (96.1%; 118.5%)
		II	26	N<50	N<50	N<50	N<50	N<50	N<50
		III	50	87.3% (78.0%; 97.6%)	83.3% (72.2%; 96.0%)	72.9% (59.8%; 88.8%)	62.9% (48.7%; 81.1%)	60.8% (46.3%; 79.8%)	57.5% (39.6%; 83.5%)
		IV	28	N<50	N<50	N<50	N<50	N<50	N<50
		X/NA	188	96.6% (93.4%; 99.8%)	94.1% (89.9%; 98.4%)	93.2% (88.4%; 98.2%)	91.4% (85.9%; 97.2%)	89.7% (83.3%; 96.6%)	80.5% (65.2%; 99.4%)
Clear-cell carcinoma		All	315	87.4% (83.6%; 91.4%)	79.4% (74.7%; 84.4%)	74.9% (69.7%; 80.4%)	72.1% (66.6%; 78.1%)	70.5% (64.6%; 77.0%)	67.5% (55.1%; 82.8%)
		I	125	96.8% (93.3%; 100.3%)	94.8% (90.3%; 99.6%)	94.3% (89.2%; 99.6%)	91.1% (84.6%; 98.1%)	88.7% (80.5%; 97.6%)	81.9% (68.0%; 98.6%)
		II	13	N<50	N<50	N<50	N<50	N<50	N<50

Net Survival Probability, 2015-2024									
Type	**Grade**	**cStage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
		III	43	N<50	N<50	N<50	N<50	N<50	N<50
		IV	28	N<50	N<50	N<50	N<50	N<50	N<50
		X/NA	106	90.9% (85.2%; 97.0%)	82.7% (75.1%; 91.1%)	78.1% (69.7%; 87.5%)	77.0% (68.2%; 87.1%)	78.3% (69.1%; 88.8%)	76.2% (57.4%; 101.1%)
Adenocarcinoma		All	333	42.9% (37.7%; 48.7%)	34.3% (29.3%; 40.1%)	26.6% (21.8%; 32.4%)	23.5% (18.8%; 29.4%)	19.0% (14.5%; 24.8%)	15.0% (10.1%; 22.3%)
		I	23	N<50	N<50	N<50	N<50	N<50	N<50
		II	2	N<50	N<50	N<50	N<50	N<50	N<50
		III	60	37.5% (27.0%; 52.1%)	31.3% (21.3%; 45.8%)	20.3% (11.8%; 35.1%)	17.4% (9.4%; 32.5%)	14.8% (7.3%; 29.8%)	FU<10y
		IV	171	33.8% (27.3%; 41.9%)	22.9% (17.2%; 30.5%)	13.5% (8.9%; 20.5%)	9.4% (5.5%; 16.1%)	2.7% (1.0%; 7.8%)	2.0% (0.6%; 6.8%)
		X/NA	77	51.8% (41.5%; 64.7%)	43.0% (32.8%; 56.4%)	42.2% (32.0%; 55.8%)	41.5% (31.2%; 55.3%)	39.0% (28.5%; 53.5%)	32.3% (19.7%; 52.8%)
Other and unspecified		All	1,085	64.3% (61.4%; 67.4%)	57.0% (53.9%; 60.2%)	51.5% (48.3%; 54.9%)	51.1% (47.8%; 54.7%)	49.6% (46.0%; 53.6%)	60.5% (53.5%; 68.5%)
		I	231	90.1% (86.0%; 94.5%)	88.4% (83.7%; 93.5%)	85.7% (80.0%; 91.8%)	84.4% (78.0%; 91.4%)	85.1% (78.4%; 92.4%)	82.3% (72.3%; 93.8%)
		II	44	N<50	N<50	N<50	N<50	N<50	N<50
		III	199	46.6% (40.0%; 54.4%)	34.7% (28.3%; 42.5%)	26.5% (20.4%; 34.4%)	24.9% (18.7%; 33.1%)	23.4% (16.4%; 33.4%)	60.5% (41.4%; 88.6%)
		IV	201	36.1% (29.9%; 43.6%)	21.8% (16.5%; 28.8%)	13.2% (8.9%; 19.7%)	12.6% (8.3%; 19.1%)	9.8% (5.8%; 16.4%)	7.6% (3.9%; 14.8%)
		X/NA	410	72.7% (68.3%; 77.4%)	66.7% (62.0%; 71.8%)	61.8% (56.8%; 67.3%)	61.8% (56.6%; 67.4%)	60.0% (54.4%; 66.2%)	62.5% (52.5%; 74.3%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<*k*years in the table.

4.2.2. Ovarian cancer survival by type and pathological stage (pStage): number at risk and net survival probabilities, 2015-2024

				Net Survival Probability, 2015-2024					
Type	**Grade**	**pStage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Ovary		All	7,540	78.8% (77.8%; 79.8%)	68.0% (66.8%; 69.1%)	58.7% (57.4%; 59.9%)	51.9% (50.6%; 53.2%)	46.8% (45.4%; 48.2%)	37.5% (35.2%; 39.9%)
		I	1,613	99.0% (98.2%; 99.8%)	97.4% (96.2%; 98.7%)	95.2% (93.5%; 96.8%)	94.0% (92.0%; 96.0%)	92.9% (90.7%; 95.3%)	87.8% (81.0%; 95.2%)
		II	440	91.9% (89.1%; 94.8%)	84.5% (80.7%; 88.4%)	80.4% (76.2%; 84.9%)	74.9% (70.0%; 80.1%)	69.6% (64.0%; 75.5%)	56.2% (46.5%; 68.0%)
		III	2,096	92.5% (91.3%; 93.8%)	80.6% (78.8%; 82.5%)	67.7% (65.5%; 70.0%)	55.9% (53.5%; 58.5%)	47.9% (45.3%; 50.6%)	33.0% (29.4%; 37.0%)
		IV	859	77.3% (74.4%; 80.3%)	60.9% (57.6%; 64.5%)	45.9% (42.4%; 49.7%)	36.2% (32.7%; 40.1%)	26.8% (23.4%; 30.6%)	16.3% (12.3%; 21.6%)
		X/NA	2,536	52.8% (50.8%; 54.8%)	38.2% (36.2%; 40.3%)	28.6% (26.7%; 30.6%)	23.4% (21.6%; 25.4%)	20.0% (18.2%; 22.0%)	14.3% (11.7%; 17.4%)
Serous carcinoma		All	4,807	81.6% (80.5%; 82.8%)	68.1% (66.7%; 69.6%)	56.0% (54.5%; 57.6%)	46.2% (44.6%; 47.9%)	39.5% (37.9%; 41.3%)	24.6% (22.3%; 27.2%)
		I	442	98.4% (96.6%; 100.2%)	94.9% (92.0%; 97.7%)	89.7% (85.9%; 93.6%)	87.0% (82.6%; 91.7%)	84.7% (79.8%; 90.0%)	75.7% (63.7%; 90.1%)
		II	254	95.4% (92.4%; 98.6%)	90.1% (85.7%; 94.6%)	84.6% (79.3%; 90.2%)	75.8% (69.4%; 82.8%)	69.6% (62.4%; 77.6%)	49.9% (37.6%; 66.2%)
		III	1,802	94.8% (93.6%; 96.0%)	83.6% (81.7%; 85.5%)	70.3% (68.0%; 72.8%)	57.1% (54.5%; 59.9%)	48.6% (45.9%; 51.6%)	27.2% (23.7%; 31.1%)
		IV	700	82.6% (79.7%; 85.6%)	66.3% (62.7%; 70.2%)	50.4% (46.5%; 54.6%)	39.2% (35.3%; 43.5%)	29.1% (25.3%; 33.5%)	17.5% (13.1%; 23.3%)
		X/NA	1,609	59.5% (57.1%; 62.1%)	40.7% (38.2%; 43.4%)	28.7% (26.4%; 31.3%)	21.2% (19.0%; 23.6%)	16.8% (14.7%; 19.1%)	7.9% (5.8%; 10.9%)
	Low-grade	All	541	85.4% (82.3%; 88.6%)	77.7% (74.0%; 81.6%)	71.3% (67.2%; 75.8%)	63.6% (59.0%; 68.5%)	57.1% (52.3%; 62.4%)	40.2% (33.1%; 48.9%)
		I	92	99.2% (97.1%; 101.3%)	100.0% (96.3%; 103.7%)	95.4% (88.9%; 102.5%)	93.8% (85.4%; 102.9%)	94.2% (85.3%; 104.1%)	85.3% (67.1%; 108.5%)
		II	25	N<50	N<50	N<50	N<50	N<50	N<50
		III	187	98.2% (95.9%; 100.6%)	95.3% (91.6%; 99.2%)	90.3% (85.0%; 95.8%)	80.9% (74.1%; 88.3%)	72.0% (64.0%; 81.0%)	50.0% (38.0%; 65.9%)
		IV	63	83.5% (74.6%; 93.5%)	73.0% (62.5%; 85.4%)	66.8% (55.5%; 80.5%)	53.4% (41.4%; 68.9%)	40.7% (29.0%; 57.1%)	13.5% (5.0%; 37.0%)
		X/NA	174	62.4% (55.4%; 70.4%)	46.4% (39.1%; 54.9%)	36.7% (29.8%; 45.3%)	29.3% (22.7%; 37.8%)	24.6% (18.4%; 32.9%)	13.2% (7.3%; 23.7%)
	High-grade	All	4,199	81.6% (80.3%; 82.8%)	67.3% (65.8%; 68.8%)	54.4% (52.7%; 56.1%)	44.2% (42.5%; 46.0%)	37.4% (35.6%; 39.2%)	22.4% (19.8%; 25.2%)
		I	345	97.8% (95.6%; 100.0%)	93.3% (89.9%; 96.8%)	88.3% (83.8%; 92.9%)	85.3% (80.2%; 90.7%)	82.1% (76.4%; 88.3%)	72.7% (58.5%; 90.5%)
		II	227	95.2% (92.0%; 98.6%)	89.6% (84.9%; 94.5%)	83.4% (77.6%; 89.5%)	74.0% (67.1%; 81.6%)	67.6% (59.9%; 76.3%)	44.5% (31.5%; 62.8%)
		III	1,611	94.4% (93.1%; 95.7%)	82.2% (80.1%; 84.3%)	67.9% (65.3%; 70.5%)	54.2% (51.4%; 57.2%)	45.9% (42.9%; 49.0%)	24.5% (21.0%; 28.6%)
		IV	634	82.6% (79.5%; 85.8%)	65.8% (61.9%; 69.8%)	48.8% (44.7%; 53.2%)	37.7% (33.6%; 42.3%)	27.9% (23.9%; 32.4%)	16.8% (12.3%; 22.7%)

Net Survival Probability, 2015-2024									
Type	**Grade**	**pStage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
		X/NA	1,382	59.8% (57.1%; 62.6%)	40.4% (37.8%; 43.3%)	27.9% (25.4%; 30.7%)	20.3% (18.0%; 23.0%)	15.7% (13.5%; 18.2%)	6.8% (4.4%; 10.3%)
	Unspecified	All	67	54.1% (43.0%; 68.1%)	42.1% (31.2%; 56.7%)	35.8% (25.3%; 50.8%)	29.1% (19.3%; 43.9%)	27.8% (18.2%; 42.6%)	23.5% (13.5%; 40.8%)
		I	5	N<50	N<50	N<50	N<50	N<50	N<50
		II	2	N<50	N<50	N<50	N<50	N<50	N<50
		III	4	N<50	N<50	N<50	N<50	N<50	N<50
		IV	3	N<50	N<50	N<50	N<50	N<50	N<50
		X/NA	53	42.6% (30.8%; 58.9%)	28.8% (18.4%; 44.9%)	22.4% (13.2%; 38.1%)	15.9% (8.2%; 30.6%)	15.9% (8.2%; 30.6%)	12.0% (5.3%; 27.4%)
Mucinous carcinoma		All	528	85.0% (81.9%; 88.3%)	80.5% (76.8%; 84.3%)	77.7% (73.7%; 81.9%)	77.1% (72.9%; 81.6%)	75.0% (70.4%; 79.9%)	69.3% (60.5%; 79.4%)
		I	353	99.1% (97.5%; 100.7%)	97.8% (95.3%; 100.5%)	97.4% (94.4%; 100.6%)	97.2% (93.7%; 100.9%)	96.1% (91.8%; 100.6%)	96.4% (85.7%; 108.6%)
		II	26	N<50	N<50	N<50	N<50	N<50	N<50
		III	43	N<50	N<50	N<50	N<50	N<50	N<50
		IV	21	N<50	N<50	N<50	N<50	N<50	N<50
		X/NA	85	48.9% (39.3%; 60.8%)	41.1% (31.8%; 53.2%)	39.0% (29.6%; 51.3%)	38.2% (28.7%; 50.8%)	36.6% (27.0%; 49.5%)	27.6% (15.6%; 49.0%)
Endometrioid carcinoma		All	478	95.8% (93.6%; 98.0%)	93.3% (90.5%; 96.3%)	91.6% (88.2%; 95.1%)	89.3% (85.3%; 93.5%)	87.0% (82.4%; 92.0%)	82.4% (70.4%; 96.5%)
		I	305	101.0% (100.0%; 102.0%)	100.4% (98.2%; 102.6%)	99.8% (96.7%; 102.9%)	98.6% (94.4%; 102.9%)	97.1% (92.0%; 102.5%)	92.7% (76.7%; 112.2%)
		II	57	92.9% (85.8%; 100.7%)	89.5% (80.7%; 99.2%)	91.6% (82.6%; 101.5%)	87.7% (76.9%; 100.0%)	86.5% (73.6%; 101.6%)	76.0% (50.3%; 114.9%)
		III	50	94.9% (88.3%; 101.9%)	83.7% (73.1%; 95.9%)	78.2% (66.3%; 92.3%)	71.6% (58.4%; 87.8%)	64.4% (50.3%; 82.4%)	51.1% (35.0%; 74.6%)
		IV	16	N<50	N<50	N<50	N<50	N<50	N<50
		X/NA	50	77.1% (65.9%; 90.3%)	77.1% (65.9%; 90.3%)	73.3% (60.4%; 89.0%)	70.4% (56.6%; 87.5%)	72.1% (58.0%; 89.7%)	77.9% (53.7%; 113.1%)
Clear-cell carcinoma		All	315	87.4% (83.6%; 91.4%)	79.4% (74.7%; 84.4%)	74.9% (69.7%; 80.4%)	72.1% (66.6%; 78.1%)	70.5% (64.6%; 77.0%)	67.5% (55.1%; 82.8%)
		I	193	97.9% (95.4%; 100.4%)	97.0% (93.7%; 100.4%)	95.6% (91.5%; 100.0%)	94.9% (89.9%; 100.1%)	95.0% (89.3%; 101.0%)	89.6% (72.5%; 110.8%)
		II	24	N<50	N<50	N<50	N<50	N<50	N<50
		III	53	83.6% (73.9%; 94.7%)	52.2% (39.8%; 68.3%)	41.5% (29.6%; 58.2%)	31.8% (20.5%; 49.1%)	25.7% (15.2%; 43.7%)	28.4% (16.7%; 48.2%)
		IV	11	N<50	N<50	N<50	N<50	N<50	N<50

Net Survival Probability, 2015-2024									
Type	**Grade**	**pStage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
		X/NA	34	N<50	N<50	N<50	N<50	N<50	N<50
Adenocarcinoma		All	333	42.9% (37.7%; 48.7%)	34.3% (29.3%; 40.1%)	26.6% (21.8%; 32.4%)	23.5% (18.8%; 29.4%)	19.0% (14.5%; 24.8%)	15.0% (10.1%; 22.3%)
		I	27	N<50	N<50	N<50	N<50	N<50	N<50
		II	7	N<50	N<50	N<50	N<50	N<50	N<50
		III	29	N<50	N<50	N<50	N<50	N<50	N<50
		IV	55	39.1% (28.0%; 54.7%)	26.4% (16.8%; 41.6%)	19.5% (10.9%; 35.0%)	15.2% (7.7%; 30.2%)	13.0% (6.1%; 27.5%)	8.5% (2.6%; 28.0%)
		X/NA	215	31.4% (25.6%; 38.4%)	21.9% (16.8%; 28.6%)	14.5% (10.2%; 20.7%)	12.2% (8.1%; 18.5%)	8.9% (5.3%; 15.0%)	6.8% (3.5%; 13.1%)
Other and unspecified		All	1,085	64.3% (61.4%; 67.4%)	57.0% (53.9%; 60.2%)	51.5% (48.3%; 54.9%)	51.1% (47.8%; 54.7%)	49.6% (46.0%; 53.6%)	60.5% (53.5%; 68.5%)
		I	294	98.3% (96.4%; 100.2%)	97.7% (95.1%; 100.3%)	96.0% (92.7%; 99.3%)	96.4% (92.9%; 100.1%)	97.3% (93.6%; 101.2%)	92.0% (83.4%; 101.6%)
		II	72	89.1% (81.6%; 97.2%)	71.6% (61.4%; 83.5%)	68.4% (57.5%; 81.3%)	66.6% (55.0%; 80.6%)	61.3% (49.0%; 76.9%)	60.1% (45.1%; 80.1%)
		III	119	75.4% (67.9%; 83.9%)	63.1% (54.5%; 72.9%)	48.4% (39.4%; 59.4%)	47.0% (37.8%; 58.6%)	45.4% (35.7%; 57.8%)	82.3% (60.4%; 112.1%)
		IV	56	63.2% (51.6%; 77.5%)	42.4% (30.9%; 58.3%)	35.5% (24.2%; 52.0%)	36.1% (24.7%; 52.9%)	26.0% (15.2%; 44.4%)	23.3% (12.3%; 44.3%)
		X/NA	544	40.3% (36.2%; 44.9%)	33.1% (29.1%; 37.7%)	27.7% (23.8%; 32.3%)	27.2% (23.1%; 32.0%)	26.1% (21.7%; 31.4%)	29.8% (21.8%; 40.7%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

4.2.3. Ovarian cancer survival by type and stage: number at risk and net survival probabilities, 2015-2024

Net Survival Probability, 2015-2024									
Type	**Grade**	**Stage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Ovary		All	7,540	78.8% (77.8%; 79.8%)	68.0% (66.8%; 69.1%)	58.7% (57.4%; 59.9%)	51.9% (50.6%; 53.2%)	46.8% (45.4%; 48.2%)	37.5% (35.2%; 39.9%)
		I	1,619	97.2% (96.2%; 98.3%)	95.8% (94.4%; 97.2%)	93.9% (92.2%; 95.6%)	92.6% (90.5%; 94.6%)	92.1% (89.8%; 94.4%)	86.4% (79.5%; 93.8%)
		II	408	88.8% (85.5%; 92.3%)	82.2% (78.0%; 86.5%)	79.0% (74.4%; 83.8%)	75.1% (69.9%; 80.6%)	68.8% (63.0%; 75.2%)	60.6% (50.2%; 73.3%)
		III	2,497	81.4% (79.8%; 83.0%)	68.5% (66.6%; 70.5%)	57.5% (55.4%; 59.7%)	47.3% (45.1%; 49.7%)	40.5% (38.2%; 42.9%)	27.9% (24.8%; 31.5%)
		IV	2,284	68.0% (66.1%; 70.1%)	51.5% (49.4%; 53.7%)	36.8% (34.6%; 39.0%)	28.2% (26.1%; 30.4%)	21.1% (19.1%; 23.2%)	11.6% (9.2%; 14.6%)
		X/NA	737	57.0% (53.4%; 60.8%)	47.9% (44.2%; 51.9%)	41.3% (37.6%; 45.4%)	38.0% (34.2%; 42.1%)	35.9% (32.0%; 40.2%)	29.5% (23.8%; 36.4%)
Serous carcinoma		All	4,807	81.6% (80.5%; 82.8%)	68.1% (66.7%; 69.6%)	56.0% (54.5%; 57.6%)	46.2% (44.6%; 47.9%)	39.5% (37.9%; 41.3%)	24.6% (22.3%; 27.2%)
		I	398	97.0% (94.8%; 99.2%)	93.5% (90.4%; 96.7%)	89.6% (85.6%; 93.7%)	86.2% (81.5%; 91.2%)	84.8% (79.5%; 90.3%)	76.1% (63.6%; 91.2%)
		II	220	94.0% (90.4%; 97.8%)	88.1% (83.2%; 93.3%)	83.7% (78.0%; 89.8%)	76.8% (70.0%; 84.2%)	69.7% (62.1%; 78.2%)	52.9% (39.6%; 70.8%)
		III	2,026	87.0% (85.5%; 88.6%)	74.1% (72.0%; 76.2%)	62.5% (60.2%; 65.0%)	50.6% (48.1%; 53.2%)	42.9% (40.3%; 45.6%)	23.6% (20.4%; 27.4%)
		IV	1,772	75.8% (73.8%; 78.0%)	58.4% (56.0%; 60.9%)	42.2% (39.7%; 44.8%)	32.1% (29.6%; 34.7%)	24.3% (22.0%; 26.9%)	12.3% (9.5%; 15.9%)
		X/NA	391	56.8% (51.9%; 62.1%)	44.0% (39.0%; 49.5%)	34.9% (30.1%; 40.5%)	28.4% (23.8%; 33.9%)	25.6% (21.1%; 31.0%)	14.8% (10.2%; 21.5%)
	Low-grade	All	541	85.4% (82.3%; 88.6%)	77.7% (74.0%; 81.6%)	71.3% (67.2%; 75.8%)	63.6% (59.0%; 68.5%)	57.1% (52.3%; 62.4%)	40.2% (33.1%; 48.9%)
		I	90	98.1% (95.1%; 101.1%)	98.7% (94.5%; 103.2%)	95.5% (89.0%; 102.5%)	93.9% (85.6%; 103.0%)	94.5% (85.6%; 104.2%)	87.4% (69.0%; 110.8%)
		II	26	N<50	N<50	N<50	N<50	N<50	N<50
		III	209	91.9% (87.9%; 96.0%)	84.9% (79.6%; 90.5%)	78.7% (72.5%; 85.5%)	69.6% (62.5%; 77.6%)	59.8% (52.0%; 68.7%)	38.2% (27.9%; 52.4%)
		IV	151	76.7% (70.0%; 84.0%)	62.3% (54.7%; 71.0%)	53.7% (45.8%; 63.0%)	41.0% (33.1%; 50.8%)	31.9% (24.3%; 41.9%)	4.8% (1.2%; 19.6%)
		X/NA	65	60.6% (49.6%; 74.1%)	54.9% (43.6%; 69.1%)	45.7% (34.5%; 60.4%)	41.3% (30.2%; 56.5%)	40.1% (29.0%; 55.5%)	28.6% (16.6%; 49.4%)
	High-grade	All	4,199	81.6% (80.3%; 82.8%)	67.3% (65.8%; 68.8%)	54.4% (52.7%; 56.1%)	44.2% (42.5%; 46.0%)	37.4% (35.6%; 39.2%)	22.4% (19.8%; 25.2%)
		I	304	96.2% (93.6%; 99.0%)	91.8% (88.0%; 95.8%)	87.6% (82.9%; 92.7%)	83.6% (78.0%; 89.5%)	81.5% (75.3%; 88.1%)	72.0% (57.1%; 90.7%)
		II	192	93.6% (89.6%; 97.7%)	87.2% (81.9%; 93.0%)	82.1% (75.8%; 88.9%)	73.9% (66.4%; 82.2%)	66.3% (58.1%; 75.8%)	43.9% (29.8%; 64.8%)
		III	1,811	86.5% (84.8%; 88.2%)	72.8% (70.6%; 75.1%)	60.7% (58.2%; 63.3%)	48.4% (45.8%; 51.2%)	41.0% (38.3%; 43.9%)	22.1% (18.7%; 26.0%)
		IV	1,607	75.7% (73.5%; 78.0%)	58.0% (55.5%; 60.7%)	41.1% (38.5%; 43.9%)	31.3% (28.7%; 34.0%)	23.6% (21.1%; 26.3%)	12.6% (9.7%; 16.3%)

Net Survival Probability, 2015-2024									
Type	**Grade**	**Stage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
		X/NA	285	59.2% (53.6%; 65.5%)	44.6% (38.8%; 51.1%)	34.3% (28.7%; 40.9%)	26.8% (21.6%; 33.3%)	23.2% (18.2%; 29.5%)	11.4% (6.6%; 19.6%)
	Unspecified	All	67	54.1% (43.0%; 68.1%)	42.1% (31.2%; 56.7%)	35.8% (25.3%; 50.8%)	29.1% (19.3%; 43.9%)	27.8% (18.2%; 42.6%)	23.5% (13.5%; 40.8%)
		I	4	N<50	N<50	N<50	N<50	N<50	N<50
		II	2	N<50	N<50	N<50	N<50	N<50	N<50
		III	6	N<50	N<50	N<50	N<50	N<50	N<50
		IV	14	N<50	N<50	N<50	N<50	N<50	N<50
		X/NA	41	N<50	N<50	N<50	N<50	N<50	N<50
Mucinous carcinoma		All	528	85.0% (81.9%; 88.3%)	80.5% (76.8%; 84.3%)	77.7% (73.7%; 81.9%)	77.1% (72.9%; 81.6%)	75.0% (70.4%; 79.9%)	69.3% (60.5%; 79.4%)
		I	357	99.1% (97.5%; 100.7%)	98.2% (95.7%; 100.7%)	97.8% (94.8%; 100.8%)	97.6% (94.1%; 101.1%)	97.0% (92.9%; 101.3%)	96.9% (86.1%; 108.9%)
		II	25	N<50	N<50	N<50	N<50	N<50	N<50
		III	59	54.0% (42.5%; 68.6%)	38.9% (28.0%; 54.0%)	31.6% (21.3%; 46.9%)	30.3% (19.9%; 46.2%)	28.0% (17.8%; 44.0%)	10.0% (3.2%; 31.7%)
		IV	52	39.5% (28.2%; 55.3%)	23.9% (14.7%; 38.9%)	15.9% (8.5%; 29.9%)	12.1% (5.8%; 25.2%)	7.9% (3.2%; 19.9%)	5.5% (1.8%; 16.7%)
		X/NA	35	N<50	N<50	N<50	N<50	N<50	N<50
Endometrioid carcinoma		All	478	95.8% (93.6%; 98.0%)	93.3% (90.5%; 96.3%)	91.6% (88.2%; 95.1%)	89.3% (85.3%; 93.5%)	87.0% (82.4%; 92.0%)	82.4% (70.4%; 96.5%)
		I	306	100.6% (99.4%; 101.8%)	99.9% (97.7%; 102.2%)	99.6% (96.6%; 102.7%)	99.1% (95.1%; 103.2%)	98.3% (93.6%; 103.4%)	91.5% (75.2%; 111.4%)
		II	53	96.2% (90.1%; 102.7%)	94.5% (86.7%; 102.9%)	96.8% (88.9%; 105.4%)	92.8% (82.4%; 104.5%)	87.1% (72.6%; 104.4%)	81.6% (54.7%; 121.7%)
		III	59	87.6% (79.2%; 97.0%)	79.4% (68.7%; 91.7%)	69.0% (56.8%; 83.7%)	61.2% (48.3%; 77.7%)	57.9% (44.6%; 75.2%)	54.0% (38.2%; 76.4%)
		IV	34	N<50	N<50	N<50	N<50	N<50	N<50
		X/NA	26	N<50	N<50	N<50	N<50	N<50	N<50
Clear-cell carcinoma		All	315	87.4% (83.6%; 91.4%)	79.4% (74.7%; 84.4%)	74.9% (69.7%; 80.4%)	72.1% (66.6%; 78.1%)	70.5% (64.6%; 77.0%)	67.5% (55.1%; 82.8%)
		I	195	97.4% (94.8%; 100.1%)	96.5% (93.1%; 100.1%)	95.2% (90.9%; 99.6%)	94.4% (89.5%; 99.6%)	94.6% (88.9%; 100.6%)	87.8% (70.9%; 108.7%)
		II	23	N<50	N<50	N<50	N<50	N<50	N<50
		III	55	75.2% (64.3%; 87.9%)	50.9% (38.9%; 66.6%)	41.3% (29.8%; 57.4%)	32.9% (21.9%; 49.5%)	25.2% (15.1%; 42.0%)	28.1% (16.8%; 47.0%)
		IV	31	N<50	N<50	N<50	N<50	N<50	N<50

Net Survival Probability, 2015-2024									
Type	**Grade**	**Stage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
		X/NA	11	N<50	N<50	N<50	N<50	N<50	N<50
Adenocarcinoma		All	333	42.9% (37.7%; 48.7%)	34.3% (29.3%; 40.1%)	26.6% (21.8%; 32.4%)	23.5% (18.8%; 29.4%)	19.0% (14.5%; 24.8%)	15.0% (10.1%; 22.3%)
		I	29	N<50	N<50	N<50	N<50	N<50	N<50
		II	6	N<50	N<50	N<50	N<50	N<50	N<50
		III	67	44.2% (33.7%; 58.0%)	37.2% (27.0%; 51.3%)	28.6% (19.1%; 42.8%)	26.7% (17.3%; 41.0%)	21.8% (13.2%; 35.9%)	14.6% (7.1%; 29.7%)
		IV	174	35.0% (28.5%; 43.1%)	24.3% (18.5%; 31.9%)	15.2% (10.4%; 22.4%)	11.4% (7.1%; 18.4%)	5.3% (2.5%; 11.2%)	2.9% (0.8%; 9.9%)
		X/NA	57	36.3% (25.5%; 51.6%)	26.1% (16.6%; 41.2%)	24.8% (15.4%; 39.9%)	24.8% (15.4%; 39.9%)	25.2% (15.1%; 41.8%)	21.1% (11.4%; 39.3%)
Other and unspecified		All	1,085	64.3% (61.4%; 67.4%)	57.0% (53.9%; 60.2%)	51.5% (48.3%; 54.9%)	51.1% (47.8%; 54.7%)	49.6% (46.0%; 53.6%)	60.5% (53.5%; 68.5%)
		I	335	92.5% (89.4%; 95.7%)	91.6% (88.1%; 95.2%)	89.3% (85.1%; 93.7%)	88.9% (84.3%; 93.7%)	89.8% (85.0%; 94.8%)	85.1% (76.7%; 94.4%)
		II	81	76.2% (66.8%; 86.9%)	65.2% (54.9%; 77.5%)	62.9% (51.6%; 76.6%)	63.1% (51.2%; 77.9%)	58.4% (45.6%; 74.9%)	63.7% (47.7%; 85.1%)
		III	231	49.5% (43.3%; 56.6%)	37.8% (31.7%; 45.0%)	29.4% (23.6%; 36.5%)	28.3% (22.4%; 35.6%)	25.9% (19.7%; 34.2%)	46.0% (32.8%; 64.7%)
		IV	221	40.2% (34.1%; 47.4%)	25.3% (19.9%; 32.1%)	15.9% (11.3%; 22.4%)	15.4% (10.8%; 22.0%)	12.1% (7.8%; 18.8%)	10.9% (6.5%; 18.2%)
		X/NA	217	56.7% (50.2%; 64.0%)	52.6% (45.9%; 60.3%)	47.6% (40.7%; 55.6%)	48.1% (41.0%; 56.5%)	47.3% (39.5%; 56.7%)	54.0% (39.4%; 74.0%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

5.1. Ovarian cancer survival trends: by tumour stage

5.1.1. Ovarian cancer survival trends by stage: number at risk and net survival probabilities, 2004-2024

Period	Stage	Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2004-2009	**All**	5,305	77.8% (76.6%; 78.9%)	56.0% (54.5%; 57.4%)	44.0% (42.5%; 45.5%)
	I	826	96.9% (95.5%; 98.4%)	92.6% (90.1%; 95.0%)	90.9% (87.8%; 94.1%)
	II	281	86.9% (82.7%; 91.2%)	68.7% (63.0%; 75.0%)	59.5% (53.4%; 66.4%)
	III	1,318	82.3% (80.1%; 84.5%)	54.6% (51.8%; 57.5%)	36.2% (33.5%; 39.2%)
	IV	884	63.8% (60.5%; 67.1%)	34.1% (31.0%; 37.6%)	19.6% (16.8%; 22.8%)
	X/NA	1,997	71.8% (69.7%; 73.9%)	49.6% (47.2%; 52.0%)	38.3% (36.0%; 40.7%)
2010-2014	**All**	4,072	77.0% (75.6%; 78.3%)	54.8% (53.2%; 56.5%)	42.7% (41.1%; 44.5%)
	I	706	96.8% (95.2%; 98.4%)	91.1% (88.4%; 93.9%)	87.8% (84.5%; 91.4%)
	II	230	87.8% (83.3%; 92.5%)	74.6% (68.4%; 81.4%)	64.2% (57.1%; 72.3%)
	III	1,245	83.8% (81.7%; 86.0%)	54.7% (51.8%; 57.7%)	36.2% (33.4%; 39.2%)
	IV	933	66.1% (63.0%; 69.3%)	35.6% (32.5%; 39.0%)	22.4% (19.7%; 25.4%)
	X/NA	958	61.4% (58.2%; 64.7%)	42.0% (38.8%; 45.5%)	32.5% (29.2%; 36.0%)
2015-2019	**All**	3,731	79.3% (77.9%; 80.6%)	59.2% (57.5%; 60.9%)	47.1% (45.3%; 49.0%)
	I	748	97.8% (96.4%; 99.2%)	95.0% (92.7%; 97.3%)	92.5% (89.4%; 95.6%)
	II	204	91.8% (87.7%; 96.0%)	80.7% (74.7%; 87.2%)	71.3% (64.0%; 79.5%)
	III	1,249	82.9% (80.7%; 85.2%)	58.2% (55.3%; 61.2%)	40.7% (37.7%; 43.8%)

Period	Stage	Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	IV	1,028	67.7% (64.8%; 70.7%)	36.9% (33.9%; 40.1%)	21.5% (19.0%; 24.4%)
	X/NA	503	60.8% (56.5%; 65.5%)	44.7% (40.2%; 49.8%)	38.1% (33.5%; 43.4%)
2020-2024	All	3,810	78.3% (77.0%; 79.7%)	58.1% (56.3%; 59.9%)	46.6% (44.4%; 48.9%)
	I	871	96.8% (95.3%; 98.2%)	92.6% (90.1%; 95.3%)	92.7% (89.4%; 96.1%)
	II	204	85.8% (80.6%; 91.2%)	77.2% (70.4%; 84.6%)	65.5% (56.2%; 76.3%)
	III	1,248	79.9% (77.5%; 82.3%)	56.8% (53.7%; 60.1%)	40.5% (36.7%; 44.7%)
	IV	1,256	68.3% (65.7%; 71.0%)	36.6% (33.6%; 39.8%)	20.4% (17.3%; 23.9%)
	X/NA	234	48.8% (42.6%; 56.0%)	33.7% (27.6%; 41.2%)	31.8% (25.1%; 40.4%)

5.2. Ovarian cancer survival trends: by tumour type and tumour stage

5.2.1. Ovarian cancer survival trends by type and stage: number at risk and net survival probabilities, 2004-2024

Period	Type	Grade	Stage	Net Survival Probability			
				N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2004-2009	Serous carcinoma		**All**	2,695	85.1% (83.7%; 86.6%)	58.0% (56.1%; 60.1%)	40.7% (38.8%; 42.8%)
			I	245	97.9% (95.5%; 100.3%)	96.2% (92.2%; 100.5%)	91.0% (84.9%; 97.5%)
			II	164	89.1% (84.1%; 94.4%)	70.3% (63.1%; 78.4%)	55.5% (47.7%; 64.5%)
			III	911	89.4% (87.2%; 91.5%)	59.4% (56.1%; 62.9%)	38.5% (35.3%; 42.1%)
			IV	500	77.2% (73.4%; 81.1%)	41.8% (37.5%; 46.6%)	23.4% (19.8%; 27.7%)
			X/NA	875	80.8% (78.1%; 83.6%)	52.7% (49.3%; 56.4%)	36.1% (32.8%; 39.7%)
		Low-grade	**All**	1,582	85.9% (84.1%; 87.8%)	57.0% (54.4%; 59.7%)	39.2% (36.7%; 41.9%)
			I	121	99.4% (97.1%; 101.7%)	97.4% (92.0%; 103.1%)	90.9% (82.5%; 100.2%)
			II	106	87.3% (80.6%; 94.5%)	68.9% (59.9%; 79.3%)	55.4% (45.8%; 66.9%)
			III	565	90.5% (87.9%; 93.2%)	58.5% (54.3%; 63.0%)	37.7% (33.7%; 42.3%)
			IV	280	77.4% (72.5%; 82.8%)	43.2% (37.5%; 49.7%)	22.6% (18.0%; 28.5%)
			X/NA	510	81.8% (78.3%; 85.4%)	50.7% (46.3%; 55.5%)	34.1% (29.9%; 38.8%)
		High-grade	**All**	309	88.4% (84.6%; 92.3%)	62.1% (56.6%; 68.2%)	41.2% (35.7%; 47.6%)
			I	19	N<50	N<50	N<50
			II	18	N<50	N<50	N<50
			III	102	87.4% (80.9%; 94.5%)	61.0% (51.8%; 72.0%)	38.5% (29.6%; 50.0%)
			IV	86	81.6% (73.5%; 90.6%)	49.0% (39.1%; 61.5%)	32.1% (23.2%; 44.5%)
			X/NA	84	91.6% (85.5%; 98.1%)	64.2% (54.1%; 76.3%)	39.3% (29.7%; 52.1%)
		Unspecified	**All**	804	82.3% (79.5%; 85.1%)	58.5% (55.0%; 62.3%)	43.6% (39.9%; 47.5%)
			I	105	94.9% (90.1%; 99.9%)	92.5% (86.0%; 99.6%)	90.2% (81.0%; 100.4%)

Period	Type	Grade	Stage	Net Survival Probability			
				N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
			II	40	N<50	N<50	N<50
			III	244	87.5% (83.1%; 92.0%)	61.0% (54.8%; 68.0%)	40.4% (34.2%; 47.6%)
			IV	134	73.7% (66.4%; 81.9%)	34.1% (26.7%; 43.6%)	19.3% (13.4%; 27.7%)
			X/NA	281	75.6% (70.6%; 81.1%)	53.0% (47.2%; 59.6%)	38.7% (32.9%; 45.4%)
	Mucinous carcinoma		**All**	519	77.5% (73.9%; 81.4%)	66.2% (61.9%; 70.8%)	62.4% (57.7%; 67.5%)
			I	198	95.7% (92.2%; 99.2%)	90.1% (84.7%; 95.9%)	91.0% (84.8%; 97.7%)
			II	26	N<50	N<50	N<50
			III	59	60.4% (49.0%; 74.4%)	39.6% (28.6%; 54.9%)	28.5% (18.2%; 44.7%)
			IV	62	44.4% (33.4%; 58.9%)	25.7% (16.7%; 39.6%)	19.5% (11.6%; 32.8%)
			X/NA	174	76.3% (70.0%; 83.2%)	64.4% (57.3%; 72.5%)	57.5% (49.9%; 66.2%)
	Endometrioid carcinoma		**All**	422	91.2% (88.2%; 94.2%)	79.5% (75.2%; 84.0%)	74.1% (69.2%; 79.3%)
			I	161	99.6% (97.5%; 101.7%)	95.1% (90.4%; 100.0%)	91.6% (85.2%; 98.5%)
			II	33	N<50	N<50	N<50
			III	76	85.4% (77.5%; 94.2%)	69.2% (58.8%; 81.5%)	54.0% (42.4%; 68.6%)
			IV	29	N<50	N<50	N<50
			X/NA	123	89.0% (83.3%; 95.1%)	74.9% (66.8%; 84.0%)	70.3% (61.7%; 80.1%)
	Clear-cell carcinoma		**All**	197	90.0% (85.6%; 94.5%)	75.0% (68.8%; 81.9%)	68.2% (61.2%; 75.9%)
			I	86	98.7% (95.5%; 101.9%)	89.2% (81.8%; 97.3%)	88.5% (80.9%; 96.9%)
			II	13	N<50	N<50	N<50
			III	27	N<50	N<50	N<50
			IV	9	N<50	N<50	N<50
			X/NA	62	84.8% (76.1%; 94.6%)	70.1% (59.1%; 83.1%)	59.1% (47.2%; 74.1%)
	Adenocarcinoma		**All**	876	56.7% (53.4%; 60.2%)	33.7% (30.5%; 37.3%)	24.5% (21.5%; 27.9%)
			I	44	N<50	N<50	N<50

Period	Type	Grade	Stage	Net Survival Probability			
				N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
			II	18	N<50	N<50	N<50
			III	151	60.4% (52.9%; 69.1%)	35.3% (28.1%; 44.4%)	22.5% (16.3%; 31.0%)
			IV	202	45.5% (39.0%; 53.1%)	19.5% (14.5%; 26.2%)	9.5% (5.9%; 15.1%)
			X/NA	461	55.5% (51.0%; 60.4%)	31.9% (27.6%; 36.8%)	23.4% (19.5%; 28.2%)
	Other and unspecified		All	596	62.0% (58.1%; 66.2%)	47.1% (42.9%; 51.7%)	41.6% (37.0%; 46.8%)
			I	92	90.3% (84.0%; 96.9%)	85.3% (77.5%; 94.0%)	84.5% (75.7%; 94.3%)
			II	27	N<50	N<50	N<50
			III	94	59.6% (50.3%; 70.7%)	34.8% (25.8%; 46.8%)	26.3% (18.3%; 37.8%)
			IV	82	41.1% (31.5%; 53.7%)	26.6% (17.7%; 40.1%)	14.7% (6.7%; 32.6%)
			X/NA	302	57.9% (52.4%; 64.0%)	43.9% (38.1%; 50.5%)	38.5% (32.6%; 45.4%)
2010-2014	Serous carcinoma		All	2,427	82.6% (81.0%; 84.2%)	56.5% (54.5%; 58.7%)	39.8% (37.7%; 42.0%)
			I	219	94.9% (91.5%; 98.4%)	89.0% (83.8%; 94.4%)	82.5% (75.8%; 89.8%)
			II	144	88.3% (82.8%; 94.3%)	77.2% (69.6%; 85.6%)	65.7% (57.2%; 75.5%)
			III	954	89.7% (87.7%; 91.9%)	59.7% (56.4%; 63.1%)	39.0% (35.7%; 42.4%)
			IV	631	76.7% (73.4%; 80.3%)	44.1% (40.2%; 48.4%)	26.8% (23.3%; 30.8%)
			X/NA	479	68.5% (64.3%; 72.9%)	45.4% (40.9%; 50.4%)	31.1% (26.9%; 35.9%)
		Low-grade	All	1,214	82.3% (80.1%; 84.7%)	55.4% (52.5%; 58.5%)	37.6% (34.8%; 40.7%)
			I	102	92.7% (87.3%; 98.6%)	87.8% (80.1%; 96.2%)	77.9% (67.9%; 89.4%)
			II	66	85.0% (76.2%; 94.9%)	73.7% (62.5%; 87.0%)	58.4% (46.1%; 74.0%)
			III	488	88.7% (85.7%; 91.8%)	58.6% (54.1%; 63.5%)	37.3% (32.9%; 42.2%)
			IV	314	80.2% (75.7%; 84.9%)	45.0% (39.6%; 51.2%)	26.4% (21.7%; 32.1%)
			X/NA	244	67.2% (61.4%; 73.6%)	43.6% (37.5%; 50.7%)	30.1% (24.5%; 37.0%)
		High-grade	All	607	85.0% (82.1%; 88.1%)	58.9% (54.8%; 63.2%)	44.2% (40.1%; 48.8%)
			I	40	N<50	N<50	N<50

Period	Type	Grade	Stage	Net Survival Probability			
				N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
			II	27	N<50	N<50	N<50
			III	264	93.8% (90.6%; 97.2%)	64.0% (58.1%; 70.5%)	45.4% (39.4%; 52.4%)
			IV	180	74.5% (68.2%; 81.5%)	43.9% (37.0%; 52.2%)	31.7% (25.1%; 39.9%)
			X/NA	96	69.7% (60.8%; 79.8%)	49.8% (40.4%; 61.5%)	35.0% (26.2%; 46.7%)
		Unspecified	**All**	606	80.5% (77.2%; 83.9%)	56.4% (52.3%; 60.8%)	39.6% (35.5%; 44.1%)
			I	77	93.9% (88.1%; 100.2%)	88.7% (80.3%; 98.1%)	86.7% (76.5%; 98.1%)
			II	51	87.1% (77.9%; 97.4%)	74.8% (62.5%; 89.5%)	64.2% (50.8%; 81.1%)
			III	202	86.9% (82.1%; 92.0%)	56.6% (49.8%; 64.3%)	34.5% (28.2%; 42.2%)
			IV	137	71.6% (64.2%; 79.9%)	42.3% (34.3%; 52.0%)	21.2% (15.0%; 30.0%)
			X/NA	139	69.7% (62.2%; 78.1%)	45.0% (37.1%; 54.6%)	29.8% (22.5%; 39.4%)
	Mucinous carcinoma		**All**	293	79.0% (74.3%; 83.9%)	65.5% (59.9%; 71.5%)	60.0% (54.1%; 66.5%)
			I	158	96.7% (93.8%; 99.8%)	94.5% (90.1%; 99.0%)	88.5% (82.3%; 95.1%)
			II	11	N<50	N<50	N<50
			III	43	N<50	N<50	N<50
			IV	40	N<50	N<50	N<50
			X/NA	41	N<50	N<50	N<50
	Endometrioid carcinoma		**All**	253	93.2% (89.8%; 96.8%)	81.2% (75.7%; 87.0%)	73.2% (66.8%; 80.2%)
			I	124	99.3% (97.1%; 101.6%)	92.4% (86.4%; 98.8%)	92.9% (86.1%; 100.3%)
			II	23	N<50	N<50	N<50
			III	51	81.1% (70.4%; 93.3%)	64.8% (52.2%; 80.4%)	33.3% (22.1%; 50.2%)
			IV	19	N<50	N<50	N<50
			X/NA	36	N<50	N<50	N<50
	Clear-cell carcinoma		**All**	161	83.8% (78.1%; 90.0%)	70.4% (63.2%; 78.5%)	64.9% (57.1%; 73.7%)
			I	76	97.5% (93.9%; 101.1%)	92.4% (85.1%; 100.2%)	91.4% (83.0%; 100.6%)

Period	Type	Grade	Stage	Net Survival Probability			
				N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
			II	13	N<50	N<50	N<50
			III	29	N<50	N<50	N<50
			IV	21	N<50	N<50	N<50
			X/NA	22	N<50	N<50	N<50
	Adenocarcinoma		All	455	52.9% (48.3%; 57.8%)	26.1% (22.1%; 30.7%)	20.1% (16.4%; 24.5%)
			I	34	N<50	N<50	N<50
			II	10	N<50	N<50	N<50
			III	94	59.7% (50.4%; 70.9%)	27.8% (19.8%; 39.0%)	20.6% (13.5%; 31.2%)
			IV	134	47.6% (39.6%; 57.2%)	15.9% (10.6%; 23.9%)	8.4% (4.7%; 14.9%)
			X/NA	183	43.0% (36.3%; 51.1%)	19.4% (14.3%; 26.4%)	14.7% (10.1%; 21.4%)
	Other and unspecified		All	484	59.7% (55.3%; 64.4%)	47.7% (43.1%; 52.8%)	44.7% (39.6%; 50.5%)
			I	96	95.3% (90.5%; 100.3%)	87.7% (80.1%; 96.1%)	86.1% (77.3%; 95.9%)
			II	29	N<50	N<50	N<50
			III	74	58.7% (48.2%; 71.4%)	35.8% (25.9%; 49.4%)	27.0% (18.0%; 40.6%)
			IV	88	26.6% (18.7%; 37.8%)	10.7% (5.8%; 19.7%)	8.4% (4.2%; 16.9%)
			X/NA	197	54.2% (47.4%; 62.0%)	44.1% (37.2%; 52.3%)	43.8% (35.5%; 54.0%)
2015-2019	Serous carcinoma		All	2,384	82.0% (80.4%; 83.7%)	56.8% (54.7%; 59.0%)	40.1% (37.9%; 42.3%)
			I	200	97.4% (94.7%; 100.2%)	90.8% (85.7%; 96.1%)	84.0% (77.3%; 91.3%)
			II	118	96.4% (92.4%; 100.6%)	85.8% (78.6%; 93.5%)	73.1% (64.0%; 83.5%)
			III	999	87.9% (85.8%; 90.2%)	62.8% (59.6%; 66.2%)	42.5% (39.2%; 46.0%)
			IV	786	75.4% (72.3%; 78.6%)	42.2% (38.7%; 46.0%)	24.8% (21.7%; 28.3%)
			X/NA	281	61.8% (56.2%; 68.1%)	39.0% (33.2%; 45.7%)	28.9% (23.5%; 35.5%)
		Low-grade	All	323	82.8% (78.5%; 87.3%)	67.1% (61.7%; 72.9%)	51.8% (46.1%; 58.2%)
			I	49	N<50	N<50	N<50

Period	Type	Grade	Stage	Net Survival Probability			
				N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
			II	16	N<50	N<50	N<50
			III	123	93.7% (88.8%; 98.8%)	80.3% (72.5%; 89.0%)	57.3% (48.2%; 68.1%)
			IV	80	68.6% (58.9%; 79.8%)	42.3% (32.4%; 55.2%)	24.8% (16.8%; 36.7%)
			X/NA	55	60.5% (48.6%; 75.4%)	44.7% (32.8%; 60.8%)	38.3% (26.7%; 54.9%)
		High-grade	**All**	2,017	82.1% (80.3%; 83.9%)	55.4% (53.1%; 57.8%)	38.2% (35.9%; 40.6%)
			I	148	96.8% (93.4%; 100.4%)	90.8% (84.9%; 97.1%)	83.5% (75.5%; 92.2%)
			II	101	96.7% (92.4%; 101.1%)	83.9% (75.9%; 92.7%)	69.7% (59.7%; 81.5%)
			III	870	87.1% (84.8%; 89.6%)	60.5% (57.0%; 64.1%)	40.5% (37.1%; 44.2%)
			IV	694	76.1% (72.8%; 79.5%)	42.3% (38.6%; 46.4%)	24.7% (21.4%; 28.4%)
			X/NA	204	62.6% (56.0%; 69.9%)	37.6% (31.0%; 45.6%)	25.9% (20.0%; 33.6%)
		Unspecified	**All**	44	N<50	N<50	N<50
			I	3	N<50	N<50	N<50
			II	1	N<50	N<50	N<50
			III	6	N<50	N<50	N<50
			IV	12	N<50	N<50	N<50
			X/NA	22	N<50	N<50	N<50
	Mucinous carcinoma		**All**	265	85.0% (80.6%; 89.6%)	76.1% (70.7%; 82.0%)	72.8% (66.7%; 79.4%)
			I	168	99.0% (97.0%; 101.0%)	96.6% (92.6%; 100.8%)	95.7% (90.4%; 101.3%)
			II	15	N<50	N<50	N<50
			III	31	N<50	N<50	N<50
			IV	25	N<50	N<50	N<50
			X/NA	26	N<50	N<50	N<50
	Endometrioid carcinoma		**All**	259	97.0% (94.3%; 99.7%)	93.5% (89.3%; 97.9%)	88.3% (82.6%; 94.5%)
			I	161	100.5% (98.6%; 102.5%)	99.4% (95.2%; 103.8%)	98.8% (92.7%; 105.3%)

Period	Type	Grade	Stage	Net Survival Probability							
				N at risk	1-y	(95%CI)	3-y	(95%CI)	5-y	(95%CI)	
			II	27	N<50		N<50		N<50		
			III	39	N<50		N<50		N<50		
			IV	11	N<50		N<50		N<50		
			X/NA	21	N<50		N<50		N<50		
	Clear-cell carcinoma		**All**	156	90.1%	(85.3%; 95.3%)	78.0%	(71.2%; 85.5%)	74.2%	(66.5%; 82.8%)	
			I	96	100.0%	(100.0%; 100.0%)	99.5%	(95.3%; 103.9%)	99.3%	(93.0%; 106.0%)	
			II	7	N<50		N<50		N<50		
			III	32	N<50		N<50		N<50		
			IV	12	N<50		N<50		N<50		
			X/NA	9	N<50		N<50		N<50		
	Adenocarcinoma		**All**	173	41.4%	(34.6%; 49.6%)	28.7%	(22.4%; 36.8%)	20.0%	(14.5%; 27.7%)	
			I	11	N<50		N<50		N<50		
			II	1	N<50		N<50		N<50		
			III	35	N<50		N<50		N<50		
			IV	95	36.9%	(28.2%; 48.2%)	19.5%	(12.7%; 30.0%)	7.1%	(3.3%; 15.3%)	
			X/NA	31	N<50		N<50		N<50		
	Other and unspecified		**All**	496	63.6%	(59.3%; 68.1%)	48.1%	(43.5%; 53.1%)	46.6%	(41.8%; 52.1%)	
			I	113	89.5%	(83.7%; 95.7%)	87.8%	(81.1%; 95.1%)	86.3%	(78.7%; 94.7%)	
			II	36	N<50		N<50		N<50		
			III	113	59.2%	(50.5%; 69.4%)	32.8%	(24.7%; 43.5%)	30.1%	(21.9%; 41.5%)	
			IV	99	42.2%	(33.4%; 53.4%)	13.8%	(8.3%; 22.8%)	11.9%	(6.8%; 20.8%)	
			X/NA	135	57.4%	(49.3%; 66.9%)	48.7%	(40.2%; 59.1%)	46.9%	(37.5%; 58.7%)	
2020-2024	Serous carcinoma		**All**	2,423	81.2%	(79.6%; 82.9%)	55.1%	(52.9%; 57.5%)	38.8%	(36.2%; 41.7%)	
			I	198	96.3%	(93.0%; 99.6%)	87.5%	(81.4%; 94.1%)	88.1%	(80.7%; 96.1%)	

Period	Type	Grade	Stage	Net Survival Probability			
				N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
			II	102	91.2% (85.1%; 97.7%)	81.3% (72.4%; 91.3%)	62.9% (50.2%; 79.0%)
			III	1,027	86.1% (83.9%; 88.5%)	62.1% (58.7%; 65.7%)	43.8% (39.6%; 48.4%)
			IV	986	76.2% (73.5%; 79.1%)	42.1% (38.7%; 45.9%)	23.6% (20.0%; 27.8%)
			X/NA	110	44.0% (35.4%; 54.7%)	24.5% (17.2%; 34.9%)	16.4% (9.4%; 28.5%)
		Low-grade	**All**	218	89.3% (85.1%; 93.8%)	77.7% (71.4%; 84.6%)	67.4% (58.7%; 77.3%)
			I	41	N<50	N<50	N<50
			II	10	N<50	N<50	N<50
			III	86	89.2% (82.6%; 96.3%)	74.8% (64.5%; 86.9%)	68.6% (55.5%; 84.7%)
			IV	71	85.8% (77.7%; 94.8%)	67.1% (56.0%; 80.5%)	39.1% (25.8%; 59.1%)
			X/NA	10	N<50	N<50	N<50
		High-grade	**All**	2,182	81.1% (79.3%; 82.8%)	53.3% (50.9%; 55.8%)	36.3% (33.5%; 39.3%)
			I	156	95.4% (91.5%; 99.5%)	83.0% (75.6%; 91.1%)	81.1% (72.3%; 90.9%)
			II	91	90.0% (83.3%; 97.3%)	80.1% (70.5%; 90.9%)	59.7% (46.2%; 77.1%)
			III	941	85.9% (83.5%; 88.3%)	60.9% (57.4%; 64.7%)	41.7% (37.4%; 46.6%)
			IV	913	75.4% (72.5%; 78.4%)	40.1% (36.6%; 44.0%)	22.4% (18.7%; 26.8%)
			X/NA	81	50.9% (40.8%; 63.4%)	25.8% (17.3%; 38.4%)	14.9% (7.5%; 29.6%)
		Unspecified	**All**	23	N<50	N<50	N<50
			I	1	N<50	N<50	N<50
			II	1	N<50	N<50	N<50
			IV	2	N<50	N<50	N<50
			X/NA	19	N<50	N<50	N<50
	Mucinous carcinoma		**All**	263	85.0% (80.6%; 89.7%)	79.4% (73.7%; 85.4%)	79.1% (72.5%; 86.5%)
			I	189	98.8% (96.4%; 101.2%)	98.2% (93.9%; 102.7%)	99.1% (93.0%; 105.6%)
			II	10	N<50	N<50	N<50

Period	Type	Grade	Stage	Net Survival Probability							
				N at risk	1-y	(95%CI)		3-y	(95%CI)	5-y	(95%CI)
			III	28	N<50			N<50		N<50	
			IV	27	N<50			N<50		N<50	
			X/NA	9	N<50			N<50		N<50	
	Endometrioid carcinoma		All	219	94.3%	(90.8%; 97.8%)		89.1%	(83.8%; 94.8%)	87.3%	(80.1%; 95.0%)
			I	145	100.0%	(98.6%; 101.3%)		99.7%	(95.6%; 104.1%)	97.0%	(89.4%; 105.3%)
			II	26	N<50			N<50		N<50	
			III	20	N<50			N<50		N<50	
			IV	23	N<50			N<50		N<50	
			X/NA	5	N<50			N<50		N<50	
	Clear-cell carcinoma		All	159	84.7%	(79.1%; 90.7%)		71.4%	(64.0%; 79.6%)	67.0%	(58.4%; 76.8%)
			I	99	93.9%	(88.9%; 99.2%)		90.3%	(83.3%; 97.9%)	89.9%	(81.2%; 99.6%)
			II	16	N<50			N<50		N<50	
			III	23	N<50			N<50		N<50	
			IV	19	N<50			N<50		N<50	
			X/NA	2	N<50			N<50		N<50	
	Adenocarcinoma		All	160	44.4%	(37.1%; 53.1%)		22.1%	(15.6%; 31.3%)	18.1%	(11.6%; 28.4%)
			I	18	N<50			N<50		N<50	
			II	5	N<50			N<50		N<50	
			III	32	N<50			N<50		N<50	
			IV	79	32.8%	(23.8%; 45.3%)		7.4%	(3.0%; 18.3%)	FU<5y	-
			X/NA	26	N<50			N<50		N<50	
	Other and unspecified		All	589	65.0%	(61.1%; 69.1%)		54.7%	(50.3%; 59.5%)	51.6%	(46.0%; 57.9%)
			I	222	93.9%	(90.4%; 97.5%)		89.5%	(84.1%; 95.3%)	90.9%	(84.8%; 97.4%)
			II	45	N<50			N<50		N<50	

Period	Type	Grade	Stage	Net Survival Probability							
				N at risk	1-y	(95%CI)	3-y	(95%CI)	5-y	(95%CI)	
			III	118	40.2%	(32.1%; 50.3%)	26.8%	(19.4%; 37.1%)	19.9%	(10.7%; 37.1%)	
			IV	122	38.5%	(30.7%; 48.4%)	20.1%	(13.3%; 30.3%)	11.2%	(5.2%; 24.4%)	
			X/NA	82	55.3%	(45.2%; 67.6%)	45.0%	(34.3%; 59.1%)	48.6%	(37.0%; 63.9%)	

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

6.1. Ovarian cancer mortality: by region

6.1.1. Ovarian cancer mortality by region: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023*

	N [CR]																				ESR2013 (95%CI)
Region	**0-**	**5-**	**10-**	**15-**	**20-**	**25-**	**30-**	**35-**	**40-**	**45-**	**50-**	**55-**	**60-**	**65-**	**70-**	**75-**	**80-**	**85-**	**90-**	**95-**	**All ages**	
Belgium	0	0	0	1	0	0	0	5	4	6	11	42	46	78	84	91	84	71	36	6	565	8.5
	[0.0]	[0.0]	[0.0]	[0.3]	[0.0]	[0.0]	[0.0]	[1.3]	[1.0]	[1.6]	[2.8]	[10.6]	[12.1]	[23.0]	[28.3]	[37.0]	[48.2]	[53.1]	[50.8]	[28.8]	[9.5]	(7.8; 9.2)
Brussels	0	0	0	0	0	0	0	0	0	0	1	6	8	11	5	2	4	5	2	1	45	8.9
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.6]	[17.6]	[26.5]	[44.0]	[23.3]	[11.1]	[31.1]	[51.0]	[35.3]	[48.0]	[7.1]	(6.2; 11.5)
Flanders	0	0	0	1	0	0	0	3	3	5	8	21	29	38	54	59	53	47	23	3	347	8.6
	[0.0]	[0.0]	[0.0]	[0.6]	[0.0]	[0.0]	[0.0]	[1.4]	[1.4]	[2.4]	[3.6]	[8.9]	[12.7]	[18.8]	[30.8]	[39.3]	[48.4]	[55.1]	[52.3]	[24.5]	[10.1]	(7.7; 9.5)
Wallonia	0	0	0	0	0	0	0	2	1	1	2	15	9	29	25	30	27	19	11	2	173	8.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.7]	[0.8]	[0.8]	[1.6]	[11.9]	[7.3]	[26.0]	[25.0]	[38.7]	[52.0]	[49.1]	[51.9]	[30.8]	[9.2]	(7.1; 9.5)

7.1. Ovarian cancer mortality trends: by region

7.1.1. Ovarian cancer mortality trends by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023*

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium	**N**	677	666	660	705	666	685	696	654	677	616	601	665	565	607	575	612	586	602	610	565		
	CR	12.8	12.5	12.3	13.0	12.2	12.5	12.6	11.7	12.0	10.9	10.6	11.7	9.9	10.5	10.0	10.5	10.0	10.3	10.4	9.5		
	ESR2013	12.9	12.5	12.3	12.9	12.0	12.1	12.2	11.2	11.4	10.4	10.1	11.1	9.3	9.8	9.1	9.6	9.2	9.3	9.3	8.5	-2.2 (-2.5; -1.8)	2004-2023
Brussels	**N**	66	38	56	55	59	57	55	54	55	45	54	51	41	37	53	36	37	40	42	45		
	CR	12.7	7.3	10.6	10.3	10.9	10.3	9.8	9.4	9.4	7.6	9.0	8.5	6.7	6.1	8.7	5.8	6.0	6.4	6.7	7.1		
	ESR2013	12.9	7.4	11.9	11.3	11.7	11.8	10.7	10.6	10.5	8.7	10.3	10.3	7.8	7.2	10.7	6.9	7.4	7.9	8.1	8.9	-2.1 (-3.3; -0.8)	2004-2023
Flanders	**N**	384	429	394	424	398	409	418	388	394	369	370	376	360	364	352	386	355	392	380	347		
	CR	12.6	14.0	12.8	13.7	12.7	13.0	13.2	12.2	12.3	11.4	11.4	11.5	11.0	11.0	10.6	11.6	10.6	11.7	11.2	10.1		
	ESR2013	12.6	13.9	12.6	13.4	12.1	12.3	12.4	11.3	11.2	10.5	10.5	10.4	9.8	9.6	9.1	10.0	9.1	9.9	9.5	8.6	-2.1 (-2.5; -1.7)	2004-2023
																						-2.5 (-3.0; -2.0)	2004-2018
																						-0.8 (-2.5; 0.9)	2019-2023
Wallonia	**N**	227	199	210	226	209	219	223	212	228	202	177	238	164	206	170	190	194	170	188	173		
	CR	13.0	11.4	11.9	12.8	11.8	12.3	12.4	11.7	12.5	11.0	9.6	12.9	8.9	11.1	9.2	10.2	10.4	9.1	10.1	9.2		
	ESR2013	13.3	11.4	11.9	12.6	12.0	12.0	12.2	11.1	12.3	10.7	9.1	12.6	8.6	10.7	8.7	9.5	9.8	8.4	9.3	8.3	-2.1 (-2.9; -1.4)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2023.

Recommended reference: Cancer Fact Sheets 2024, Belgian Cancer Registry (BCR), 2026